Heron Therapeutics Inc
AXD2
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
7 undervalued US stocks that crushed earnings
Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued ASX share hitting on all cylinders
Strong performance across all segments in latest earnings release.
stocks
Investor Playbook: Can your portfolio handle what’s next?
Testing portfolio resilience in an uncertain market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,372.15 | 3.24 | 0.04% |
| DAX 40 | 26,654.74 | 95.21 | -0.36% |
| Dow JONES (US) | 52,011.74 | 335.81 | -0.64% |
| FTSE 100 | 10,916.82 | 14.26 | 0.13% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,635.02 | 501.26 | -1.99% |
| Nikkei 225 | 59,662.02 | 1,480.33 | -2.42% |
| NZX 50 Index | 14,303.77 | 130.09 | 0.92% |
| S&P 500 | 7,463.48 | 98.19 | -1.30% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |